A Randomized, Placebo-Controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors - dal-PLAQUE


Despite multiple attempts, no pharmacological agent thus far has been successful in increasing high-density lipoprotein (HDL) while reducing coronary events. Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that has not shown off-target effects such as blood pressure elevation (noted with torcetrapib, another CETP inhibitor in the ILLUSTRATE and ILLUMINATE trials) in early trials.

The current trial was a phase II trial designed to assess the efficacy and s...